» Articles » PMID: 26668022

Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD

Overview
Specialty Nephrology
Date 2015 Dec 16
PMID 26668022
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Ultrasonographic detection of subclinical atheromatosis is a noninvasive method predicting cardiovascular events. Risk factors predicting atheromatosis progression in CKD are unknown. Predictors of atheromatosis progression were evaluated in patients with CKD.

Design, Setting, Participants, & Measurements: Our multicenter, prospective, observational study included 1553 patients with CKD (2009-2011). Carotid and femoral ultrasounds were performed at baseline and after 24 months. A subgroup of 476 patients with CKD was also randomized to undergo ultrasound examination at 12 months. Progression of atheromatosis was defined as an increase in the number of plaque territories analyzed by multivariate logistic regression.

Results: Prevalence of atheromatosis was 68.7% and progressed in 59.8% of patients after 24 months. CKD progression was associated with atheromatosis progression, suggesting a close association between pathologies. Variables significantly predicting atheromatosis progression, independent from CKD stages, were diabetes and two interactions of age with ferritin and plaque at baseline. Given that multiple interactions were found between CKD stage and age, phosphate, smoking, dyslipidemia, body mass index, systolic BP (SBP), carotid intima-media thickness, plaque at baseline, uric acid, cholesterol, 25-hydroxy vitamin D (25OH vitamin D), and antiplatelet and phosphate binders use, the analysis was stratified by CKD stages. In stage 3, two interactions (age with phosphate and plaque at baseline) were found, and smoking, diabetes, SBP, low levels of 25OH vitamin D, and no treatment with phosphate binders were positively associated with atheromatosis progression. In stages 4 and 5, three interactions (age with ferritin and plaque and plaque with smoking) were found, and SBP was positively associated with atheromatosis progression. In dialysis, an interaction between body mass index and 25OH vitamin D was found, and age, dyslipidemia, carotid intima-media thickness, low cholesterol, ferritin, and uric acid were positively associated with atheromatosis progression.

Conclusions: Atheromatosis progression affects more than one half of patients with CKD, and predictive factors differ depending on CKD stage.

Citing Articles

Carotid plaque thickness predicts cardiovascular events and death in patients with chronic kidney disease.

Bjergfelt S, Sorensen I, Urbak L, Kofoed K, Lange T, Feldt-Rasmussen B BMC Nephrol. 2024; 25(1):389.

PMID: 39482658 PMC: 11526655. DOI: 10.1186/s12882-024-03831-4.


Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial.

Donate-Correa J, Ferri C, Mora-Fernandez C, Perez-Delgado N, Gonzalez-Luis A, Navarro-Gonzalez J Cardiovasc Diabetol. 2024; 23(1):314.

PMID: 39182114 PMC: 11344929. DOI: 10.1186/s12933-024-02393-x.


The relationship between asymptomatic atherosclerosis and hepcidin-25 in chronic kidney disease patients.

Mohamed O, Mady A, Sedik M, Issa A, Mohamed O, Abdelhameed N Ann Saudi Med. 2023; 43(5):298-308.

PMID: 37805814 PMC: 10560366. DOI: 10.5144/0256-4947.2023.298.


Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study.

Saito Y, Tanaka A, Ishizu T, Yoshida H, Kubota Y, Nanasato M Sci Rep. 2023; 13(1):10927.

PMID: 37407666 PMC: 10322958. DOI: 10.1038/s41598-023-37183-0.


Association of Intima-Media Thickness Measured at the Common Carotid Artery With Incident Carotid Plaque: Individual Participant Data Meta-Analysis of 20 Prospective Studies.

Tschiderer L, Seekircher L, Izzo R, Mancusi C, Manzi M, Baldassarre D J Am Heart Assoc. 2023; 12(12):e027657.

PMID: 37301757 PMC: 10356054. DOI: 10.1161/JAHA.122.027657.


References
1.
Nakano T, Ninomiya T, Sumiyoshi S, Fujii H, Doi Y, Hirakata H . Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis. 2009; 55(1):21-30. DOI: 10.1053/j.ajkd.2009.06.034. View

2.
Chang A, Kramer H . Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction. Nephron Clin Pract. 2011; 119(2):c171-7. DOI: 10.1159/000325669. View

3.
Suki W . Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr. 2007; 18(1):91-8. DOI: 10.1053/j.jrn.2007.10.019. View

4.
Arroyo D, Betriu A, Martinez-Alonso M, Vidal T, Valdivielso J, Fernandez E . Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrol. 2014; 15:168. PMC: 4210528. DOI: 10.1186/1471-2369-15-168. View

5.
Herzog C . Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome. Kidney Int Suppl. 2003; (84):S197-200. DOI: 10.1046/j.1523-1755.63.s84.17.x. View